Cross-Sector entity
GLP-1 is most often covered alongside Novo Nordisk, which appears in 4 of these 10 stories. The 168-day window averages about 0.4 stories each week. The busiest single day carried 2. The clearest coverage concentration is pharma: 3 of 10 stories, with the rest divided among 4 other categories.
10 verified stories tracked
Last mentioned: Aug 10, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 20 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
GLP-1 is most often covered alongside Novo Nordisk, which appears in 4 of these 10 stories. The 168-day window averages about 0.4 stories each week. The busiest single day carried 2. The clearest coverage concentration is pharma: 3 of 10 stories, with the rest divided among 4 other categories. The tracked stories average 2.7 original sources each. 40% of these stories carry negative sentiment. This profile follows 10 Cross-Sector stories mentioning GLP-1 across the period from February 24, 2026 to August 10, 2026.
Computed from the 10 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering GLP-1. Shared-story counts are live from our verified record — not editorial picks.
Lawsuit filed
Novo Nordisk sues Eli Lilly in federal court, alleging misleading advertising.
Cease-and-desist letter
Novo Nordisk sends a formal request to Eli Lilly to stop running or correct certain ads.
Settlement Reached
Hims & Hers agrees to stop selling compounded GLP-1s to resolve legal disputes.
High-dose Wegovy approved
Novo Nordisk’s high-dose obesity injection enters the market, achieving weight loss more comparable to Zepbound.
Payer Agreement Shift
New payer contracts take effect, shifting GTN expectations to the high 30% range for the fiscal year.
Q4 Milestone
Patient count surpasses 36,000 and quarterly revenue exceeds $320 million.
Patent Extension
Secured Rezdiffra patent protection through 2045.
DGAT-2 and siRNA Expansion
Acquired late-stage DGAT-2 inhibitor and six preclinical siRNA assets.
GLP-1 Strategic Acquisition
Madrigal makes a $120 million upfront payment for an oral GLP-1 asset to expand its metabolic pipeline.
GLP-1 Acquisition
Madrigal paid $120 million upfront to acquire an oral GLP-1 program.
Rezdiffra Commercial Launch
First full year of Rezdiffra availability in the U.S. market for MASH.
Rezdiffra Full-Year Launch
Madrigal begins its first full year of commercial sales for the first-ever approved MASH treatment.
Litigation Surge
Novo Nordisk and Eli Lilly file multiple lawsuits against compounding pharmacies and telehealth firms.
FDA Shortage Updates
FDA begins removing specific GLP-1 dosages from the national shortage list.
HIMS Launches GLP-1s
Hims & Hers enters the weight-loss market with compounded GLP-1 offerings.
Novo Nordisk’s soaring obesity drug volumes—up 70% year-over-year—signal escalating demand for energy-intensive pharmaceutical manufacturing. While expanding access to GLP-1 therapies may reduce long-term healthcare burdens, the immediate production ramp-up presents sustainability challenges that the pharma sector must address.
Novo Nordisk’s Q2 earnings reveal explosive uptake of its oral Wegovy pill, now commanding 90% of the U.S. oral obesity market with 267,000 weekly scripts. The therapy is expanding the GLP-1 market, with 80% of users being treatment-naïve, signaling a new era in obesity pharmacotherapy.
Source: tickerreport.com · finance.yahoo.com
Novo Nordisk alleges Eli Lilly’s comparative advertising for Zepbound relies on outdated clinical data, violating the Lanham Act. The case could redefine how quickly pharma competitors must update ad claims when new drug formulations enter the market.
The FDA has issued a formal warning letter to Novo Nordisk for failing to properly report serious adverse events, including deaths and strokes, related to its GLP-1 medications. This regulatory escalation coincides with a significant market valuation decline and intensifying competition from compounding pharmacies.
Source: gulfcoastnewsnow.com · koco.com
Hims & Hers Health has agreed to cease the sale of compounded GLP-1 medications as part of a legal settlement, marking a significant shift in its weight-loss business strategy. This move follows mounting pressure from pharmaceutical manufacturers and highlights the tightening regulatory environment for telehealth platforms leveraging drug shortages.
Hims & Hers Health has agreed to cease the sale of compounded GLP-1 medications as part of a legal settlement, marking a significant shift in the telehealth landscape. This move follows intense regulatory scrutiny and litigation regarding the legality of compounding patented weight-loss drugs during supply shortages.
Source: wfmynews2.com · 12news.com
Agilent reported a 4.4% core revenue growth in Q1 2026, driven by a strong 7% uptick in the pharmaceutical sector despite an 8% decline in academic and government markets. The company is navigating margin pressures from new tariffs while leaning into high-growth areas like GLP-1 manufacturing and CDMO services.
Agilent Technologies reported a resilient Q1 2026 with $1.8 billion in revenue, driven by a 7% growth in the pharma sector despite significant headwinds in academic and government funding. While the company faced a 100-basis-point gross margin compression due to rising tariffs and weather disruptions, strong performance in the Agilent CrossLab Group suggests a shift toward service-oriented recurring revenue.
Source: Motley Fool Transcribing (us) · Motley Fool Transcribing (us)
Madrigal Pharmaceuticals reported a transformative 2025, with Rezdiffra net sales reaching $958.4 million during its first full year on the market. The company is aggressively pivoting toward a multi-asset metabolic powerhouse, integrating oral GLP-1 and DGAT-2 programs alongside its core MASH franchise.
Madrigal Pharmaceuticals reported a transformative Q4 2025, with Rezdiffra net sales reaching $321.1 million and a patient base exceeding 36,000. The company is aggressively expanding its metabolic pipeline, integrating GLP-1 and siRNA technologies to solidify its leadership in the MASH market.
Source: Motley Fool Transcribing (us) · Motley Fool Transcribing (us)
